[CAS NO. 15826-37-6] Cromolynsodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [15826-37-6]

Catalog

HY-B0320A

Brand

MCE

CAS

15826-37-6

DESCRIPTION [15826-37-6]

Overview

MDL	MFCD22575281
Molecular Weight	512.33
Molecular Formula	C23H14Na2O11
SMILES	OC(COC1=C2C(C=C(C(O[Na])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O[Na])=O)OC4=CC=C3)=O

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a GSK-3β inhibitor with an IC ₅₀ of 2.0 µM.

IC50 & Target

GSK-3β

2 μM (IC ₅₀ )

In Vitro

Cromolyn sodium (Disodium Cromoglycate; FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pretreatment of IIR mice with Cromolyn sodium (Disodium Cromoglycate; FPL-670) prior to ischemia exhibited no changes of ET-1 levels, injury score and inflammation (P>0.05, PreCr vs. M groups). In conclusion, administration of Cromolyn (sodium) after reperfusion, but not prior to ischemia, attenuates IIRI by downregulating ET-1 and suppressing sustained MC activation ^[1] . Cromolyn (sodium) has a role in the prevention of Chronic lung disease(CLD). Cromolyn (sodium) cannot be recommended for the prevention of CLD in preterm infants ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04428775	AZTherapies, Inc.	Amyotrophic Lateral Sclerosis	September 8, 2020	Phase 2
NCT04846348	Joseph Butterfield\|Mayo Clinic	Cutaneous Mastocytoses	July 26, 2021	Phase 2
NCT03167216	Northwestern University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Chronic Prostatitis With Chronic Pelvic Pain Syndrome	August 1, 2017	Early Phase 1
NCT04570644	AZTherapies, Inc.	Healthy Volunteers\|Alzheimer Disease	August 28, 2020	Phase 1
NCT01933464	University of California, San Diego	Papulopustular Rosacea	August 2013	Phase 1\|Phase 2
NCT02371941	University of Tennessee	Eosinophilic Esophagitis	December 2014	Phase 4
NCT05077917	Texas Tech University Health Sciences Center, El Paso	COVID-19 Pneumonia\|COVID-19 Respiratory Infection\|Pneumonia, Viral	November 15, 2021	Phase 3
NCT02566252	Pulmotect, Inc.\|WCCT Global	Healthy	July 2015	Phase 1
NCT03202147	AZTherapies, Inc.	Ischemic Stroke\|Post-stroke Cognitive Impairment	December 2023	Phase 2
NCT01175525	Wolfson Medical Center	Acute Stroke		Phase 3
NCT00745199	Shiraz University of Medical Sciences	End Stage Renal Disease\|Pruritus	May 2008	Phase 2
NCT01841307	University of California, San Francisco\|Aradign Corportation\|National Heart, Lung, and Blood Institute (NHLBI)	Gastroesophageal Reflux\|Respiratory Aspiration\|Idiopathic Pulmonary Fibrosis\|Lung Transplantation	July 2015	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 97.59 mM ; Need ultrasonic)

DMSO : 25 mg/mL ( 48.80 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9519 mL	9.7593 mL	19.5187 mL
5 mM	0.3904 mL	1.9519 mL	3.9037 mL
10 mM	0.1952 mL	0.9759 mL	1.9519 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 50 mg/mL (97.59 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4H-1-Benzopyran-2-carboxylic acid, 5,5′-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-, sodium salt (1:2)

4H-1-Benzopyran-2-carboxylic acid, 5,5′-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-, disodium salt

4H-1-Benzopyran-2-carboxylic acid, 5,5′-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-, disodium salt

FPL 670

Cromolyn sodium

Disodium cromoglycate

Disodium 5,5′-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-carboxylate]

Intal

Lomudal

Sodium cromoglycate

1,3-Bis(2-carboxychromon-7-yloxy)-2-hydroxypropane disodium salt

Disodium chromoglycate

Cromoglycate

Disodium 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol

Disodium 1,3-bis(2-carboxy-5-chromonyloxy)-2-propanol

Sodium cromolyn

Disodium 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane

Aarane

Nalcrom

Cromoglycate disodium

DSCG

DNCG

Opticrom

NasalCrom

Inostral

Sofro

Cromolyn disodium salt

Alercrom

Lomusol

Lomupren

Colimune

Alerion

Allergocrom

Cromovet

Vividrin

Crolom

Fivent

Nasmil

Rynacrom

Nalcron

Gastrofrenal

Lomuspray

Irtan

Introl

Gastrocrom

Fisonair

Altoderm

Intal UD

Nasotal

Intal Forte